{"DataElement":{"publicId":"2005506","version":"4","preferredName":"Common Toxicity Criteria Adverse Event HypothyroidismGrade","preferredDefinition":"in CTC category Endocrine, assessment of the severity of a low thyroid function or hypothyroidism adverse event using a graded scale.","longName":"CTC_AE_HYPOTHYR_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192666","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hypothyroidism","preferredDefinition":"information related to the CTC adverse event of hypothyroidism.","longName":"CTC_AE__HYPOTHYROID","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192664","version":"1","preferredName":"Hypothyroidism","preferredDefinition":"The clinical syndrome that results from decreased secretion of thyroid hormone from the thyroid gland. It leads to a slowing of metabolic processes and in its most severe form to the accumulation of mucopolysaccharides in the skin, causing a nonpitting edema termed myxedema. Cretinism is the congenital form leading to abnormalities of intellectual and physical development. (Bennett, et al., Cecil Textbook of Medicine, 20th ed)","longName":"Hypothyroidism","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Hypothyroidism","conceptCode":"C0020676","definition":"The clinical syndrome that results from decreased secretion of thyroid hormone from the thyroid gland. It leads to a slowing of metabolic processes and in its most severe form to the accumulation of mucopolysaccharides in the skin, causing a nonpitting edema termed myxedema. Cretinism is the congenital form leading to abnormalities of intellectual and physical development. (Bennett, et al., Cecil Textbook of Medicine, 20th ed)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9FACB72-0199-2CA4-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-30","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9FACB72-019F-2CA4-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017706","version":"3","preferredName":"Common Toxicity Criteria Adverse Event Hypothyroidism Grade","preferredDefinition":"in CTC category Endocrine, assessment of the severity of a low thyroid function or hypothyroidism adverse event using a graded scale.","longName":"CTC_AE_HYPOTHYR_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"Symptomatic, not interfering with ADL; thyroid replacement indicated","ValueMeaning":{"publicId":"2566545","version":"1","preferredName":"Symptomatic, not interfering with ADL; thyroid replacement indicated","longName":"2566545","preferredDefinition":"Symptomatic, not interfering with ADL; thyroid replacement indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B24B-401A-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B249-401A-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptoms interfering with ADL; hospitalization indicated","ValueMeaning":{"publicId":"2566546","version":"1","preferredName":"Symptoms interfering with ADL; hospitalization indicated","longName":"2566546","preferredDefinition":"Symptoms interfering with ADL; hospitalization indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0FF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B24D-401A-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Asymptomatic, intervention not indicated","ValueMeaning":{"publicId":"2566455","version":"1","preferredName":"Asymptomatic, intervention not indicated","longName":"2566455","preferredDefinition":"Asymptomatic, intervention not indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-11","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B24F-401A-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Life-threatening myxedema coma","ValueMeaning":{"publicId":"2566547","version":"1","preferredName":"Life-threatening myxedema coma","longName":"2566547","preferredDefinition":"Life-threatening myxedema coma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D100-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B251-401A-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"ABSENT","ValueMeaning":{"publicId":"2563534","version":"1","preferredName":"ABSENT","longName":"2563534","preferredDefinition":"ABSENT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C53B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-23","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-10-23","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B5A18F-B253-401A-E034-0003BA12F5E7","beginDate":"2003-01-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4B5A18F-B245-401A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Hypothyroidism Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"},{"name":"CTC Adverse Event Thyroid fun","type":"Preferred Question Text","description":"CTC Adverse Event Thyroid function low (hypothyroidism) Grade","url":null,"context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4B5A18F-B254-401A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-11-30","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}